このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Clinical Observation on the Efficacy of Acupoint Force Therapy Devices in the Intervention of Chronic Pelvic Pain

2026年9月19日 更新者:Peking University Third Hospital

The present study is a prospective,single-center, single-arm, pre-post control clinical trial conducted at Peking University Third Hospital. 20 participants will be recruited into CCP group,Clinical outcomes will be evaluated at baseline, one week and two weeks after treatment and two weeks follow-up after treatment termination.

The primary outcome measure is the Visual Analogue Scale (VAS) pain score before and after treatment. Secondary outcomes include Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), Numerical Rating Scale (NRS), SF-36 Health Survey, Short-form McGill Pain Questionnaire (SF-MPQ), adverse event incidence rate, and analgesic medication use frequency.Adverse events will be assessed at every visit. Both the CRF and web-based electronic database, REDCap (edc.bjmu.edu.cn), will be used to manage individual participant data by two data entry personnel independently. SPSS V.25.0 statistical software was used for analysis. This report describes the study design of the clinical trial.

調査の概要

状態

まだ募集していません

詳細な説明

Chronic pelvic pain (CPP) is defined as non-cyclic pain localized in the pelvic region, primarily involving the lower abdomen and lumbosacral area, persisting for more than 6 months. In 2020, the American College of Obstetricians and Gynecologists (ACOG) consensus classified the etiologies of CPP into three major categories: organ diseases, neuromusculoskeletal abnormalities, and psychosocial factors. CPP is a challenging condition estimated to affect 15%-26% of the female population worldwide. Both patients and clinicians often feel frustrated by the limited treatment options available. Furthermore, chronic pelvic pain frequently overlaps with non-pelvic pain conditions (such as fibromyalgia and migraines) as well as non-painful comorbidities (including sleep disorders, mood disorders, and cognitive dysfunction), thereby exacerbating pain severity and leading to functional impairment. A wide array of clinical therapeutic regimens is available, consisting of pharmacotherapy, physical therapy, cognitive-behavioral interventions, and surgery tailored to specific patient populations. Nevertheless, current therapeutic strategies are hampered by inconsistent efficacy and substantial clinical difficulties, stemming from multifactorial etiologies, poor long-term medication adherence coupled with severe adverse effects, as well as the tendency of the condition to persist and recur frequently. Therefore, there is a clinical need for safer, more effective treatment regimens suitable for long-term intervention.

Acupoint massage achieves meridian regulation and analgesic effects through manual stimulation; it is non-invasive, safer, and more acceptable to patients. Nevertheless, traditional manual acupoint massage is similarly constrained by practitioner experience variability, difficulties in standardizing pressure intensity, and substantial time and labor demands on medical staff, making it difficult to achieve stable, quantifiable, and long-term sustainable treatment requirements. Therefore, intelligent technology-based acupoint mechanical stimulation devices capable of precise control over stimulation intensity, frequency, and duration provide a new technological pathway for the sustained and standardized management of chronic pain.

EMMA is a non-invasive acupoint mechanical stimulation device designed for standardized surface intervention. It measures patients' muscle hardness through sensors and 3D vision, identifies pressure points, and provides precise acupoint stimulation to help patients relieve pain and release tension. Our team participated in a study led by Professor Claudia Witt's research group on the effectiveness of app-based acupoint acupressure therapy for women with menstrual pain. In that study, 221 women were divided into an acupoint pressure group and a usual care group, receiving acupressure intervention over 6 menstrual cycles (6 acupoints, 1 minute per acupoint, continuous pressure for 5 days before menstruation). The results showed that the average pain intensity in the third menstrual cycle was significantly lower in the acupressure group compared to the usual care group, with significant differences observed by the sixth cycle. These findings indicate that acupoint pressure can effectively reduce lower abdominal pain during menstruation, providing a theoretical basis for the conduct of this study.

Accordingly, based on preliminary research findings, this project adopts the EMMA acupoint mechanical therapy device for patient treatment, with the objective of evaluating the efficacy and safety of this device in managing chronic pelvic pain. Improvements in patients' symptoms will be assessed via changes in outcome measures including the Visual Analogue Scale (VAS) for pain.

The present study is a prospective,single-center, single-arm, pre-post control clinical trial design with a 2-week study duration. The interventions to be tested are EMMA Massage Therapy(3 times/week for a total of 6 sessions over 2 weeks). Participants will be enrolled at at Peking University Third Hospital, Beijing China.

The design of this study is compliant with the Consolidated Standards of Reporting Trials (CONSORT) guidelines and with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement 2013(Table 1). The study protocol has been approved by the Regional Ethical Review Board of Peking University Third Hospital, China. Approval Number: ID: M20260476.

CCP is characterized by pain and tenderness in the lower abdomen and lumbosacral region. Pathologically, CPP involves chronic inflammation and adhesions of pelvic organs, persistent myofascial tension in the pelvic floor muscles, and a hyperactive state of pain transmission pathways due to central sensitization; these three factors interact synergistically, leading to chronic and diffuse pain. Therefore, treatment requires simultaneous intervention at both peripheral and central levels. From the perspective of Traditional Chinese Medicine Meridian theory, the lower abdomen falls under the jurisdiction of the Ren Meridian, while the lumbosacral region is governed by the Bladder Meridian and Du Meridian-the distribution of CPP pain closely corresponds to the pathways of these meridians. Based on the above, our specific plan is as follows:

①Back acupoint massage (30 minutes) Based on the pathway of the Foot Taiyang Bladder Meridian on the back, the treatment duration is 30 minutes. The massage pressure is set at 30N as the baseline, taking into account the patient's tolerance.

②Abdominal acupoint and tender point massage Based on meridian-disease correlations and expert consensus, we selected Zhongwan (CV12), bilateral Tianshu (ST25), bilateral Guilai (ST29), Guanyuan (CV4), and relevant tender points (Ashi points) for massage in a clockwise sequence. The massage pressure is set at 30 N as the baseline, adjusted according to patient tolerance. And the treatment duration per acupoint is 1 minute as the baseline. Both the pressure and duration may be adjusted according to the patient's individual condition, and additional tender points may be included as appropriate based on the participant's presentation.

研究の種類

介入

入学 (推定)

20

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Haolin Zhang, Doctor
  • 電話番号:Ext.86 15611963539
  • メール:zoe@bjmu.edu.cn

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

20年~50年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Meet the diagnostic criteria for chronic pelvic pain;
  2. Disease duration greater than 6 months;
  3. Female patients aged 20-50 years;
  4. Married or unmarried with history of sexual activity;
  5. Not concurrently participating in other clinical studies;
  6. Voluntarily participate in this trial and provide signed informed consent. Note: Patients must meet all 6 criteria above to be enrolled in this study.

Exclusion Criteria:

  1. Altered consciousness, inability to cooperate and complete the study, or presence of psychiatric disorders;
  2. Concomitant severe diseases of the cardiovascular, cerebrovascular, hepatic, renal, urinary, digestive, or reproductive systems;
  3. Concomitant severe spine-related conditions, such as spinal fracture, spinal infection, severe osteoporosis, spondylolisthesis, or spinal instability;
  4. Presence of skin lesions, infections, ulcers, or severe dermatological conditions in the treatment area;
  5. Pregnant, planning pregnancy, or lactating women;
  6. Abdominal, pelvic, lumbar, or pelvic-related surgery or invasive procedures within the past 12 months;
  7. Currently participating in other clinical trials. Note: Individuals meeting any one of the above criteria shall be excluded.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:All participants will recept EMMA treatment in EMMA treatment

The present study is a prospective,single-center, single-arm, pre-post control clinical trial design with a 2-week study duration. The interventions to be tested are EMMA Massage Therapy.Participants will recive 3 times/week for a total of 6 sessions over 2 weeks.

①Back acupoint massage (30 minutes) Based on the pathway of the Foot Taiyang Bladder Meridian on the back, the treatment duration is 30 minutes. The massage pressure is set at 30N as the baseline, taking into account the patient's tolerance.The specific acupoints are illustrated in the figure below.

②Abdominal acupoint and tender point massage Based on meridian-disease correlations and expert consensus, we selected Zhongwan (CV12), bilateral Tianshu (ST25), bilateral Guilai (ST29), Guanyuan (CV4), and relevant tender points (Ashi points) for massage in a clockwise sequence. The massage pressure is set at 30 N as the baseline, adjusted according to patient tolerance. And the treatment duration per acupoint is 1 minute as the baseline. Both the pressure and duration may be adjusted according to the patient's individual condition, and additional tender points may be included as appropriate based on the participant's presentation.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The primary outcome is the Visual Analogue Scale (VAS) at week 2 (end of treatment).A scale of 0-10 represents different degrees of pain, with 0 representing "no pain" and 10 representing "unbearable pain."
時間枠:We will administer VAS scale assessments at four time point: basline, After 1 week of treatment, 2 weeks of treatment and follow-up 2 weeks after last treatment : All baseline measures are repeated measures.

The primary outcome is the Visual Analogue Scale (VAS) at week 2 (end of treatment).A scale of 0-10 represents different degrees of pain, with 0 representing "no pain" and 10 representing "unbearable pain." Patients mark the position corresponding to their pain severity on the scale; higher scores indicate more severe pain.

We will administer VAS scale assessments at four time point: basline, After 1 week of treatment, 2 weeks of treatment and follow-up 2 weeks after last treatment : All baseline measures are repeated measures.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月30日

一次修了 (推定)

2027年3月31日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2026年9月9日

QC基準を満たした最初の提出物

2026年9月19日

最初の投稿 (実際)

2026年9月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月19日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • Peking UTH

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Given that the data involves patient privacy and the relevant parameters of the EMMA device, the IPD data of this study will not be shared.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する